Oncology Medical News about low-dose interferon alfa-2b;lymph node-negative melanoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prospective randomized multicenter adjuvant Dermatologic Cooperative Oncology Group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma
Journal of Clinical Oncology, 05/15/09

Hauschild A et al. - In a study to assess the use of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in pts with lymph node-negative melanoma, it was found that the addition of a 4-wk modified high-dose IFN-α (HDI) induction phase to a 2-yr low-dose adjuvant IFN-α-2b treatment schedule did not improve clinical outcome.

Methods

In an attempt to investigate the potential role of a modified high-dose induction phase, lymph node–negative pts with resected primary malignant melanoma of more than 1.5-mm tumor thickness were included in this trial.
674 pts were randomly assigned to receive 4 wks of a modified HDI scheme.
This schedule consisted of 5 times weekly 10 MU/m2 IFN-α-2b IV for 2 wks and 5 times weekly 10 MU/m2 IFN-α-2b administered subcutaneously (SC) for another 2 wks followed by 23 mos of low-dose IFN-α-2b (LDI) 3 MU SC 3 times a wk (arm A).
LDI 3 MU 3 times a week was given for 24 mos in arm B.

Results

Of 650 assessable pts, there were 92 relapses among the 321 pts receiving high-dose induction vs 95 relapses among the 329 pts receiving LDI only.
5-yr relapse-free survival rates were 68.0% (arm A) and 67.1% (arm B), respectively.
Melanoma-related fatalities were similar between both groups, resulting in 5-yr overall survival rates of 80.2% (arm A) and 82.9% (arm B).

<< Previous
Adjuvant chemotherapy in older women with early-stage breast...

Next >>
Allogeneic cord blood transplantation in children with...